Laxido (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

The primary active component, macrogol 3350, is a large, non‑absorbable polymer that creates an osmotic gradient, retaining water in the intestinal lumen. The accompanying electrolytes help maintain fluid balance while the increased water content softens stool and stimulates peristalsis.

The dose of Laxido is individualized by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Patients should follow the prescriber’s instructions and the product label for preparation and administration.

Safety data for Laxido in pregnancy and lactation are limited. It should only be used if clearly needed and after a risk‑benefit assessment by a qualified healthcare provider. Women who are pregnant or breastfeeding should discuss alternatives with their doctor.

To place an order, submit an enquiry on the Laxido product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Laxido, containing macrogol 3350, is an osmotic laxative that generally provides a gentler, more predictable effect compared with stimulant laxatives such as bisacodyl. It is less likely to cause cramping and is suitable for long‑term use, whereas stimulant agents act quickly but may lead to dependence.

Laxido should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture. Keep the product away from direct sunlight and out of reach of children.

Laxido is supplied as a powder that is dissolved in water according to the instructions on the label. The solution is taken orally, usually once daily, or as directed by a healthcare professional for bowel preparation protocols.

Serious risks include severe electrolyte disturbances such as hyperkalaemia or hyponatraemia, dehydration, and rare allergic reactions that may present as rash, swelling or anaphylaxis. Patients with renal impairment or intestinal obstruction should be monitored closely.

Laxido is contraindicated in patients with known hypersensitivity to any component, in those with intestinal obstruction, perforation, or severe inflammatory bowel disease, and in individuals with significant renal failure unless closely supervised by a physician.